INVO Fertility (IVF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IVF SEC filings page.
INVO Fertility, Inc. (IVF) reported $6.8M in revenue for fiscal year 2025, up 4.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Very high reported gross margins are overwhelmed by overhead and financing costs, leaving the business loss-making with tight near-term liquidity.
FY2025 revenue was nearly flat, but net loss widened from$9.3M to$23.3M . Operating loss was still about$7.2M , so the earnings collapse was not simply a sales problem: below-operating-line items and other non-operating effects became much more consequential.
Cash conversion remains weak: operating cash flow was
The current ratio was 0.3x, with current liabilities of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of INVO Fertility, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
INVO Fertility, Inc. held $4.5M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $7.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and INVO Fertility, Inc. scores 27/100 among other emerging companies.
Not available for INVO Fertility, Inc., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Not available for INVO Fertility, Inc., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
INVO Fertility, Inc. reported revenue of $6.8M in fiscal year 2025, against $6.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and INVO Fertility, Inc. scores 78/100 among other emerging companies.
INVO Fertility, Inc.'s operations used $7.0M of cash in fiscal year 2025, against $3.0M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and INVO Fertility, Inc. scores 31/100 among other emerging companies.
INVO Fertility, Inc.'s cash, cash equivalents and investments came to $4.5M at the end of fiscal year 2025, against $13.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and INVO Fertility, Inc. scores 37/100 among other emerging companies.
INVO Fertility, Inc. scores -7.51, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $91.4M against total assets of $20.2M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
INVO Fertility, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
INVO Fertility, Inc. reported a net loss of $23.3M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
INVO Fertility, Inc. reported an operating loss of $7.2M against $1.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
INVO Fertility, Inc. generated $2.2M in revenue in Q2 2026. This represents an increase of 16.7% from the same quarter a year earlier. Against the prior quarter it is up 8.0%.
INVO Fertility, Inc.'s EBITDA was -$1.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
INVO Fertility, Inc. reported $889K in net income in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
INVO Fertility, Inc. held $3.7M in cash against $513K in long-term debt as of Q2 2026, with $6.5M of liabilities due within a year.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
INVO Fertility, Inc.'s gross margin was 97.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.
INVO Fertility, Inc.'s operating margin was -59.3% in Q2 2026, reflecting core business profitability. Against the prior quarter it is up 19.7 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
INVO Fertility, Inc.'s net profit margin was 40.8% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
INVO Fertility, Inc.'s quarterly ROE was 5.4% in Q2 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 42.3 percentage points.
Capital Allocation
None of these metrics is reported for Q2 2026.
IVF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M+16.7% | $2.0M+23.1% | $1.6M-6.1% | $1.8M+22.6% | $1.9M+1.5% | $1.6M+3.9% | $1.7M+22.0% | $1.4M+47.0% |
| Cost of Revenue | $60K+1863.7% | $5K+29.3% | N/A | N/A | $3K-99.6% | $4K-99.5% | -$2.7M-346.6% | $988K+70.1% |
| Gross Profit | $2.1M+13.7% | $2.0M+23.1% | N/A | N/A | $1.9M+90.8% | $1.6M+128.7% | $4.4M+1371.2% | $445K+12.9% |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | $266K+5343.9% | N/A | N/A |
| SG&A Expenses | $1.9M-13.1% | $2.2M+39.7% | $1.8M-26.4% | $2.1M+40.5% | $2.2M-17.2% | $1.6M+8.1% | $2.5M+32.7% | $1.5M+20.5% |
| Operating Income | -$1.3Mn/m | -$1.6Mn/m | -$1.4Mn/m | -$1.6Mn/m | -$3.0Mn/m | -$1.2Mn/m | -$2.0Mn/m | -$1.3Mn/m |
| EBITDA | -$1.1Mn/m | -$1.4Mn/m | -$1.3Mn/m | -$1.5Mn/m | -$2.8Mn/m | -$965Kn/m | -$1.7Mn/m | -$1.1Mn/m |
| Interest Expense | $177K-59.8% | $180K-41.4% | $408K+93.6% | $146K-46.7% | $441K+19.2% | $308K+69.8% | $211K+15.7% | $274K-22.3% |
| Income Tax | $56K | $0n/m | N/A | N/A | N/A | $0-100.0% | N/A | $29K+1451.4% |
| Net Income | $889Kn/m | -$5.5Mn/m | $1.1Mn/m | -$3.4Mn/m | -$3.6Mn/m | -$17.4Mn/m | -$3.8Mn/m | -$1.6Mn/m |
| EPS (Basic) | $0.42 | -$3.38 | $472.78 | -$39.40 | -$364.23 | -$3473.93 | N/A | -$15.11 |
| EPS (Diluted) | $0.35 | -$3.38 | $472.78 | -$39.40 | -$364.23 | -$3473.93 | N/A | -$15.11 |
| Diluted Shares (Avg) | 3M | 2M | N/A | 3M | 9,936 | 5,010 | N/A | 107,949 |
IVF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.8M+33.7% | $24.7M-22.3% | $20.2M-56.1% | $18.8M+10.7% | $19.3M+8.8% | $31.7M+83.1% | $46.1M+149.0% | $17.0M-0.1% |
| Current Assets | $4.6M+228.9% | $5.7M+265.4% | $2.8M+119.8% | $1.1M-41.9% | $1.4M-41.6% | $1.6M-9.0% | $1.3M-0.3% | $2.0M+9.2% |
| Cash & Equivalents | $3.7M+579.7% | $4.9M+483.6% | $2.1M+235.4% | $356K-28.8% | $549K-39.0% | $840K+76.9% | $620K+166.5% | $500K-52.6% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $251K+18.2% | $225K+3.7% | $225K+2.5% | $192K-20.6% | $213K-15.0% | $216K-18.8% | $220K-16.9% | $242K-5.0% |
| Accounts Receivable | $258K+6.4% | $248K+43.1% | $217K+92.1% | $274K+6.7% | $242K-5.8% | $174K-1.9% | $113K-19.5% | $257K+120.1% |
| Long-Term Investments | $2.5M0.0% | $2.5Mn/m | $2.5Mn/m | $2.5Mn/m | $2.5Mn/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $9.3M+57.4% | $6.5M-26.7% | $5.9M0.0% | $5.9M0.0% | $5.9M0.0% | $8.9M+51.2% | $5.9M0.0% | $5.9M-28.5% |
| Total Liabilities | $9.3M-64.7% | $9.6M-83.7% | $13.0M-50.1% | $13.0M-23.6% | $26.5M+61.5% | $58.9M+240.1% | $26.0M+47.8% | $17.0M+2.3% |
| Current Liabilities | $6.5M-46.3% | $6.4M-66.0% | $10.3M-42.2% | $9.1M+5.4% | $12.1M+52.6% | $18.7M+112.7% | $17.9M+123.3% | $8.7M+85.4% |
| Non-Current Liabilities | $2.8M-80.3% | $3.3M-91.9% | $2.7M-67.4% | $3.9M-53.6% | $14.3M+69.9% | $40.2M+371.5% | $8.2M-15.0% | $8.4M-30.1% |
| Long-Term Debt | $513K-50.7% | $660K | $745K-34.0% | $952K | $1.0M | N/A | $1.1M | N/A |
| Total Equity | $16.5Mn/m | $15.0Mn/m | $7.2M-42.6% | $5.8Mn/m | -$7.2M-624.6% | -$27.2M-267975.4% | $12.6M+1309.5% | -$23K-106.3% |
| Retained Earnings | -$96.0Mn/m | -$96.9Mn/m | -$91.4Mn/m | -$92.2Mn/m | -$90.2Mn/m | -$84.9Mn/m | -$67.3Mn/m | -$63.5Mn/m |
IVF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1Mn/m | -$1.9Mn/m | $25Kn/m | -$1.8Mn/m | -$1.7Mn/m | -$3.5Mn/m | -$617Kn/m | -$641Kn/m |
| Depreciation & Amortization | $146K-14.2% | $143K-39.1% | $136K-41.1% | $137K-40.7% | $170K-26.3% | $234K+3.3% | $232K+63.7% | $230K+1024.1% |
| Capital Expenditures | N/A | N/A | $12K-85.0% | $8Kn/m | $9K-83.9% | $15K-70.5% | $79K+5.2% | $0-100.0% |
| Free Cash Flow | N/A | N/A | $13Kn/m | -$1.8Mn/m | -$1.7Mn/m | -$3.6Mn/m | -$696Kn/m | -$641Kn/m |
| Investing Cash Flow | -$2Kn/m | -$210Kn/m | -$2.7M-788.7% | -$8Kn/m | -$15Kn/m | -$15Kn/m | $393K+1080.9% | $0n/m |
| Financing Cash Flow | -$68K-104.7% | $5.0M+35.4% | $4.4M+791.4% | $1.6M+839.0% | $1.4M-25.2% | $3.7M+593.9% | $494Kn/m | $169K-96.2% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
IVF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.2%-2.6pp | 99.7%0.0pp | N/A | N/A | 99.8%+46.8pp | 99.8%+54.4pp | 260.1% | 31.0%-9.4pp |
| Operating Margin | -59.3% | -79.0%-5.7pp | -89.2% | -93.1%-2.3pp | -160.4% | -73.3%+22.4pp | -116.6% | -90.7%+0.2pp |
| Net Margin | 40.8% | -274.9% | 69.2% | -193.3% | -194.2% | -1063.0% | -224.6% | -113.8% |
| Return on Equity | 5.4% | -36.9% | 15.2%+45.2pp | -58.4% | N/A | N/A | -30.1%+193.3pp | N/A |
| Return on Assets | 3.4%+22.2pp | -22.5%+32.4pp | 5.4%+13.6pp | -18.0%-8.4pp | -18.7%-6.1pp | -54.8%-45.6pp | -8.2%+2.6pp | -9.6%-2.2pp |
| Current Ratio | 0.71+0.6x | 0.90+0.8x | 0.27+0.2x | 0.12-0.1x | 0.12-0.2x | 0.08-0.1x | 0.07-0.1x | 0.23-0.2x |
| Debt-to-Equity | 0.03 | 0.04 | 0.100.0x | 0.16 | N/A | N/A | 0.09 | N/A |
| Liabilities-to-Equity | 0.57 | 0.64 | 1.80-0.3x | 2.24 | N/A | N/A | 2.07-17.7x | N/A |
| Asset Turnover | 0.080.0x | 0.080.0x | 0.080.0x | 0.090.0x | 0.100.0x | 0.050.0x | 0.040.0x | 0.080.0x |
| FCF Margin | N/A | N/A | 0.9%+42.1pp | -101.6% | -92.6%-10.4pp | -217.5% | -41.3%+15.9pp | -44.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.27), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| INVO Fertility, Inc. IVF | FY2025 | $6.8M | -$23.3M | N/A | $2.3M | 43/100 |
| Nuwellis, Inc. NUWE | FY2025 | $8.3M | -$17.5M | N/A | $2.3M | 46/100 |
Where INVO Fertility, Inc. Ranks
Frequently Asked Questions
What is INVO Fertility, Inc.'s annual revenue?
INVO Fertility, Inc. (IVF) reported $6.8M in total revenue for fiscal year 2025. This represents a 4.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is INVO Fertility, Inc.'s revenue growing?
INVO Fertility, Inc. (IVF) revenue grew by 4.7% year-over-year, from $6.5M to $6.8M in fiscal year 2025.
Is INVO Fertility, Inc. profitable?
No, INVO Fertility, Inc. (IVF) reported a net loss of $23.3M in fiscal year 2025.
What is INVO Fertility, Inc.'s EBITDA?
INVO Fertility, Inc. (IVF) had EBITDA of -$6.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does INVO Fertility, Inc. have?
As of fiscal year 2025, INVO Fertility, Inc. (IVF) had $2.1M in cash and equivalents against $745K in long-term debt.
What is INVO Fertility, Inc.'s gross margin?
INVO Fertility, Inc. (IVF) had a gross margin of 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is INVO Fertility, Inc.'s return on equity (ROE)?
INVO Fertility, Inc. (IVF) has a return on equity of -322.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is INVO Fertility, Inc.'s free cash flow?
INVO Fertility, Inc. (IVF) recorded an outflow of $7.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is INVO Fertility, Inc.'s operating cash flow?
INVO Fertility, Inc. (IVF) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are INVO Fertility, Inc.'s total assets?
INVO Fertility, Inc. (IVF) had $20.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are INVO Fertility, Inc.'s capital expenditures?
INVO Fertility, Inc. (IVF) invested $43K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is INVO Fertility, Inc.'s current ratio?
INVO Fertility, Inc. (IVF) had a current ratio of 0.27 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is INVO Fertility, Inc.'s debt-to-equity ratio?
INVO Fertility, Inc. (IVF) had a debt-to-equity ratio of 0.10 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is INVO Fertility, Inc.'s liabilities-to-equity ratio?
INVO Fertility, Inc. (IVF) had a liabilities-to-equity ratio of 1.80 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is INVO Fertility, Inc.'s return on assets (ROA)?
INVO Fertility, Inc. (IVF) had a return on assets of -115.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is INVO Fertility, Inc.'s P/E ratio?
INVO Fertility, Inc. (IVF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.3M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is INVO Fertility, Inc.'s price-to-sales ratio?
INVO Fertility, Inc. (IVF) trades at 0.3x sales, its market capitalization divided by $7.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.3M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does INVO Fertility, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, INVO Fertility, Inc. (IVF) held $4.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is INVO Fertility, Inc.'s Altman Z-Score?
INVO Fertility, Inc. (IVF) has an Altman Z-Score of -7.51, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is INVO Fertility, Inc.'s Piotroski F-Score?
INVO Fertility, Inc. (IVF) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are INVO Fertility, Inc.'s earnings high quality?
INVO Fertility, Inc. (IVF) reported a net loss of $23.3M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can INVO Fertility, Inc. cover its interest payments?
INVO Fertility, Inc. (IVF) reported an operating loss of $7.2M against $1.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is INVO Fertility, Inc.?
INVO Fertility, Inc. (IVF) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For INVO Fertility, Inc. it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.